Anavex announces 3 years of treatment with blarcamesine show reduced decline

Anavex (AVXL) Life Sciences announced that over three years of continuous treatment with blarcamesine demonstrated significantly reduced clinical decline showing continued clinically and meaningful benefit for early Alzheimer’s disease patients. “Long-term clinical ATTENTION-AD study results support the importance of continued long-term blarcamesine treatment,” said Prof. Dr. Timo Grimmer, MD, member of the Anavex Scientific Advisory Board and National Coordinating Investigator for the blarcamesine Phase IIb/III ANAVEX 2-73-AD-004 study. “Blarcamesine is easily scalable and might be a potential therapeutic solution for Alzheimer’s disease patients to potentially offer hope and relief and equitable and accessible for diverse populations and maintaining sustainability within the global healthcare systems.” Delayed-start analysis of treatment with oral blarcamesine was significant reflecting importance of early treatment initiation; Blarcamesine exhibited a favorable safety profile with no treatment-related deaths